Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2234Neoplasms 2039Lung Neoplasms 1097Colorectal Neoplasms 1036Prostatic Neoplasms 894Carcinoma, Non-Small-Cell Lung 752Carcinoma, Hepatocellular 674Stomach Neoplasms 607Pancreatic Neoplasms 602Head and Neck Neoplasms 434Ovarian Neoplasms 430Colonic Neoplasms 423Rectal Neoplasms 406Uterine Cervical Neoplasms 403Esophageal Neoplasms 347Brain Neoplasms 329Neoplasm Metastasis 324Melanoma 306Multiple Myeloma 304Precursor Cell Lymphoblastic Leukemia-Lymphoma 293Urinary Bladder Neoplasms 290Leukemia, Myeloid, Acute 278Lymphoma 268Liver Neoplasms 253Endometrial Neoplasms 253Hematologic Neoplasms 252Disease 244Recurrence 225Glioma 218Carcinoma, Renal Cell 207

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Observational × HER2 Overexpression × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡